Form 4: BioAtla CFO Reports Tax-Related Share Withholding

BioAtla CFO Christian Vasquez reported the withholding of common stock shares to satisfy tax obligations following the vesting of restricted stock units.

Summary

• CFO Christian Vasquez reported two transactions involving the withholding of common stock shares.
• 175 shares were withheld on March 11, 2026, at a price of $0.169 per share.
• 82 shares were withheld on May 31, 2026, at a price of $3.93 per share.
• The transactions were for tax withholding purposes related to the vesting of restricted stock units, not open-market sales.
• The reporting person's total beneficial ownership is 10,347 shares following these transactions.
• The filing notes a 50-for-1 share consolidation effective April 6, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing, as the transactions are mandatory tax withholdings and do not reflect discretionary trading activity.

Positives

• Transactions were mandatory tax withholdings rather than discretionary sales, indicating no change in the executive's long-term confidence in the company.

Negatives

• The significant variance in share price between March and May 2026 reflects high volatility in the company's stock price.

Risks

• High stock price volatility as evidenced by the price difference between the March and May transactions.
• Potential impact of the 50-for-1 share consolidation on liquidity and market perception.

Future Outlook

No specific forward-looking guidance provided in this regulatory filing.

Management Comments

• The transactions represent shares withheld by the Issuer to satisfy income tax and withholding obligations in connection with the vesting of restricted stock units.

Industry Context

StockSavvy.ai notes that tax-related share withholding is a standard administrative procedure for executives and does not typically signal a change in corporate strategy or insider sentiment regarding company performance.

Comparison to Industry Standards

• The use of net settlement for RSU vesting is a standard practice among U.S. publicly traded biotechnology companies to manage tax liabilities for employees.

Corporate Governance

Stakeholder Impact

• Shareholders should note the share consolidation adjustment when calculating historical ownership or valuation metrics.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

BioAtla, BCAB, CFO, Insider Trading, Form 4, Share Consolidation, Tax Withholding